Ayvakit (Avapritinib): Uses, Side Effects & Warnings

Key Takeaways

• Ayvakit (avapritinib) is FDA-approved for certain gastrointestinal stromal tumors and advanced systemic mastocytosis.
• It works by selectively inhibiting mutant KIT and PDGFRA kinases that drive tumor growth.
• Common side effects include edema, nausea, fatigue, cognitive effects, and intracranial bleeding risk.
• Dose adjustments are often necessary due to drug interactions, particularly with CYP3A4 inhibitors and inducers.
• Women of childbearing potential must use effective contraception, as avapritinib can cause fetal harm.

What Is Ayvakit (Avapritinib) Used to Treat?

Ayvakit (avapritinib) is a precision oncology medicine that selectively targets and inhibits the KIT and
platelet-derived growth factor receptor alpha (PDGFRA) kinases, which are frequently mutated in certain
cancers. By blocking the activity of these abnormal proteins, it disrupts the signaling pathways that allow
tumor cells to proliferate unchecked. The drug was developed by Blueprint Medicines and received approval
from the U.S. Food and Drug Administration (FDA).

The FDA first approved avapritinib in January 2020 for adults with unresectable or metastatic
gastrointestinal stromal tumors (GIST) harboring a PDGFRA exon 18 mutation, including D842V mutations.
This approval was notable because PDGFRA D842V-mutant GIST had historically shown resistance to standard
imatinib-based therapies, leaving patients with very limited options. In 2021, the FDA further approved
avapritinib for adults with advanced systemic mastocytosis (AdvSM), including aggressive systemic
mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast cell leukemia.

GIST is one of the most common soft-tissue sarcomas of the gastrointestinal tract, with approximately
4,000 to 6,000 new cases diagnosed annually in the United States, according to estimates from the American
Cancer Society. Systemic mastocytosis, though rarer, involves the abnormal accumulation of mast cells in
organs such as the bone marrow, liver, and spleen, causing significant morbidity. Avapritinib addresses
both conditions through the same underlying mechanism of KIT D816V kinase inhibition, which is central to
mast cell activation in systemic mastocytosis.

Ayvakit (Avapritinib) Side Effects and Warnings

Like all targeted therapies, avapritinib carries a spectrum of side effects, ranging from manageable
nuisances to serious medical concerns requiring immediate attention. Clinical trial data reported that the
majority of patients experienced at least one adverse event, making proactive monitoring and communication
with a healthcare provider critically important.

The most frequently reported side effects observed in clinical trials include peripheral and periorbital
edema, nausea, fatigue, decreased appetite, diarrhea, vomiting, hair color changes, and cognitive
effects such as memory impairment and confusion. Intracranial hemorrhage is among the most serious risks
and has been observed in patients using this drug, warranting caution particularly in those with bleeding
disorders or those on anticoagulant therapy. The FDA label includes a specific warning about the risk of
intracranial bleeding, and patients experiencing sudden headaches, visual disturbances, or neurological
changes should seek immediate care.

Additional Ayvakit side effects and warnings include embryo-fetal toxicity. Avapritinib has demonstrated
the potential to cause fetal harm based on its mechanism of action and animal study data. Women of
reproductive potential are advised to use highly effective contraception during treatment and for a defined
period after the last dose. Male patients with female partners of childbearing potential should also use
contraception during and after therapy. Breastfeeding is not recommended during treatment.

Cognitive and Neurological Effects

A distinctive category of adverse effects associated with avapritinib involves the central nervous system.
Patients have reported cognitive impairment, including difficulties with memory, concentration, and word
recall. In some cases, mood changes and sleep disturbances were also noted. These effects, sometimes
grouped under the term “CNS effects,” occurred across varying grades of severity and occasionally required
dose reduction or treatment interruption to manage effectively. Patients should be counseled about these
risks before starting therapy, and caregivers should be informed to help monitor for early signs.

Fluid Retention and Edema

Fluid retention is among the most commonly reported physical side effects. Periorbital edema, which refers
to swelling around the eyes, and peripheral edema affecting the limbs were both observed frequently in
clinical studies. While these effects are generally manageable through supportive care and, in some cases,
diuretics, patients with pre-existing cardiovascular conditions should be monitored with heightened
vigilance. Reporting new or worsening swelling promptly allows for timely adjustments in care.

Dosage, Drug Interactions, and Precautions for Avapritinib

Avapritinib dosage and safety information varies depending on the specific indication. For PDGFRA exon
18 mutant GIST, the recommended dose is 300 mg taken orally once daily on an empty stomach. For advanced
systemic mastocytosis, the recommended starting dose is 200 mg once daily, also taken on an empty stomach,
at least one hour before or two hours after a meal. Tablets should not be crushed or split. Missed doses
should be skipped if the next scheduled dose is within twelve hours.

Ayvakit drug interactions and precautions center primarily on cytochrome P450 3A4 (CYP3A4) enzyme
activity. Strong and moderate CYP3A4 inhibitors, such as certain antifungals, antibiotics, and
grapefruit products, can significantly increase avapritinib plasma concentrations, heightening the risk of
adverse effects. Conversely, strong and moderate CYP3A4 inducers, including rifampin and some
anticonvulsants, can substantially reduce drug levels, potentially compromising efficacy. Co-administration
of these agents should be avoided or managed with appropriate dose modifications as guided by a clinician.

Patients with moderate to severe hepatic impairment may require dose adjustments, as the drug is
extensively metabolized in the liver. Renal impairment has not been shown to significantly affect
pharmacokinetics based on available data, though clinical judgment remains necessary. Proton pump
inhibitors and other drugs that alter gastric pH may also influence absorption. The following table
summarizes key dosing considerations:

Indication	Recommended Dose	Key Adjustment Factor
PDGFRA Exon 18 Mutant GIST	300 mg once daily (fasted)	Reduce dose with strong CYP3A4 inhibitors
Advanced Systemic Mastocytosis	200 mg once daily (fasted)	Avoid strong CYP3A4 inducers
Moderate Hepatic Impairment	Dose reduction may be required	Monitor liver function closely

Avapritinib for Gastrointestinal Stromal Tumor and Systemic Mastocytosis

Avapritinib for gastrointestinal stromal tumor represents a significant therapeutic
advancement, particularly for patients whose tumors harbor the PDGFRA D842V mutation. Prior to its
approval, this mutation conferred resistance to virtually all available tyrosine kinase inhibitors,
including imatinib, sunitinib, and regorafenib. Clinical trial data from the NAVIGATOR study demonstrated
an overall response rate exceeding 85% in patients with PDGFRA D842V-mutant GIST treated with avapritinib,
a result that was unprecedented for this patient population.

Ayvakit for systemic mastocytosis treatment addresses an equally challenging disease
landscape. Advanced systemic mastocytosis is driven predominantly by the KIT D816V mutation, present in
more than 90% of affected patients. This mutation leads to constitutive KIT kinase activation and
uncontrolled mast cell proliferation. Avapritinib potently inhibits KIT D816V, which distinguishes it
mechanistically from earlier-generation agents such as midostaurin. The PATHFINDER trial demonstrated
meaningful response rates, with a significant proportion of patients achieving a reduction in bone marrow
mast cell burden and improvement in disease-related symptoms.

Beyond response rates, the impact on quality of life represents an important clinical outcome in both
conditions. Patients with systemic mastocytosis often experience debilitating symptoms including flushing,
anaphylaxis, bone pain, and fatigue. Tumor regression in GIST can alleviate pressure-related pain and
improve functional status. Clinicians typically evaluate response through imaging, bone marrow biopsy
findings, and serum tryptase levels, the latter being a key biomarker in systemic mastocytosis management.
Treatment decisions should always be made in collaboration with an oncology or hematology specialist
experienced in these rare conditions.

Frequently Asked Questions

Can avapritinib be taken with food?

Avapritinib should be taken on an empty stomach, at least one hour before or two hours after eating.
Food can increase drug absorption in ways that may raise the risk of adverse effects. Patients should
also avoid grapefruit and grapefruit juice throughout treatment, as these can inhibit CYP3A4 metabolism
and increase drug plasma levels. Following these instructions consistently helps ensure predictable
pharmacokinetics and reduces the likelihood of dose-related complications.

How is treatment response monitored during avapritinib therapy?

Response monitoring depends on the indication. In GIST, imaging studies such as CT or MRI scans are
used at regular intervals to assess tumor size and characteristics. In systemic mastocytosis, clinicians
monitor serum tryptase levels, bone marrow biopsy results, and clinical symptom scores. Complete blood
counts and liver function tests are also performed routinely, as avapritinib can affect hematologic
parameters and hepatic enzymes. Regular follow-up appointments are essential throughout the course of
treatment.

Is avapritinib safe for older adults?

Clinical trials included patients aged 65 and older, and no overall differences in efficacy were
observed compared to younger patients. However, older adults may be at higher risk for certain side
effects, including cognitive effects, edema, and falls related to neurological changes. Dose
modifications may be needed based on tolerability, renal function, and concomitant medications.
A thorough geriatric assessment and close communication with the prescribing oncology team are
recommended when initiating avapritinib in elderly patients.